127 related articles for article (PubMed ID: 9724373)
1. Feasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography.
Moore JV; Waller ML; Zhao S; Dodd NJ; Acton PD; Jeavons AP; Hastings DL
Eur J Nucl Med; 1998 Sep; 25(9):1248-54. PubMed ID: 9724373
[TBL] [Abstract][Full Text] [Related]
2. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose.
Tatsumi M; Nakamoto Y; Traughber B; Marshall LT; Geschwind JF; Wahl RL
Cancer Res; 2003 Oct; 63(19):6252-7. PubMed ID: 14559811
[TBL] [Abstract][Full Text] [Related]
3. High-resolution PET imaging for in vivo monitoring of tumor response after photodynamic therapy in mice.
Lapointe D; Brasseur N; Cadorette J; La Madeleine C; Rodrigue S; van Lier JE; Lecomte R
J Nucl Med; 1999 May; 40(5):876-82. PubMed ID: 10319764
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography--a study evaluating [18F]Fluoro-2-deoxy-D-glucose.
Bentzen L; Keiding S; Horsman MR; Falborg L; Hansen SB; Overgaard J
Acta Oncol; 2000; 39(5):629-37. PubMed ID: 11093372
[TBL] [Abstract][Full Text] [Related]
5. Deciphering PDT-induced inflammatory responses using real-time FDG-PET in a mouse tumour model.
Cauchon N; Hasséssian HM; Turcotte E; Lecomte R; van Lier JE
Photochem Photobiol Sci; 2014 Oct; 13(10):1434-43. PubMed ID: 25058054
[TBL] [Abstract][Full Text] [Related]
6. In vivo magnetic resonance imaging of the effects of photodynamic therapy.
Dodd NJ; Moore JV; Poppitt DG; Wood B
Br J Cancer; 1989 Aug; 60(2):164-7. PubMed ID: 2765361
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4.
Zhao S; Moore JV; Waller ML; McGown AT; Hadfield JA; Pettit GR; Hastings DL
Eur J Nucl Med; 1999 Mar; 26(3):231-8. PubMed ID: 10079313
[TBL] [Abstract][Full Text] [Related]
8. Predicting efficacy of photodynamic therapy by real-time FDG-PET in a mouse tumour model.
Cauchon N; Turcotte E; Lecomte R; Hasséssian HM; Lier JE
Photochem Photobiol Sci; 2012 Feb; 11(2):364-70. PubMed ID: 22234417
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy.
Sun X; Yan Y; Liu S; Cao Q; Yang M; Neamati N; Shen B; Niu G; Chen X
J Nucl Med; 2011 Jan; 52(1):140-6. PubMed ID: 21149494
[TBL] [Abstract][Full Text] [Related]
11. [Is 18F-FDG-PET suitable for therapy monitoring after palliative photodynamic therapy of non-resectable hilar cholangiocarcinoma?].
Müller D; Wiedmann M; Kluge R; Berr F; Mössner J; Sabri O; Caca K
Z Gastroenterol; 2005 May; 43(5):439-43. PubMed ID: 15871065
[TBL] [Abstract][Full Text] [Related]
12. Radiolabelled 5'-iodo-2'-deoxyuridine: a promising alternative to [18F]-2-fluoro-2-deoxy-D-glucose for PET studies of early response to anticancer treatment.
Carnochan P; Brooks R
Nucl Med Biol; 1999 Aug; 26(6):667-72. PubMed ID: 10587105
[TBL] [Abstract][Full Text] [Related]
13. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
14. Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma.
Benyounes H; Smith FW; Campbell C; Evans NT; Norton MY; Mikecz P; Heys SD; Bruce D; Eremin O; Sharp PF
Nucl Med Commun; 1995 Jul; 16(7):575-80. PubMed ID: 7478396
[TBL] [Abstract][Full Text] [Related]
15. Schwannoma of the extremities: the role of PET in preoperative planning.
Ahmed AR; Watanabe H; Aoki J; Shinozaki T; Takagishi K
Eur J Nucl Med; 2001 Oct; 28(10):1541-51. PubMed ID: 11685498
[TBL] [Abstract][Full Text] [Related]
16. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma.
Hoffmann M; Vogelsang H; Kletter K; Zettinig G; Chott A; Raderer M
Gut; 2003 Mar; 52(3):347-51. PubMed ID: 12584214
[TBL] [Abstract][Full Text] [Related]
17. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-D-glucose in murine models of breast cancer.
Aliaga A; Rousseau JA; Cadorette J; Croteau E; van Lier JE; Lecomte R; Bénard F
Mol Imaging Biol; 2007; 9(3):144-50. PubMed ID: 17334852
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer.
Moadel RM; Nguyen AV; Lin EY; Lu P; Mani J; Blaufox MD; Pollard JW; Dadachova E
Breast Cancer Res; 2003; 5(6):R199-205. PubMed ID: 14580255
[TBL] [Abstract][Full Text] [Related]
19. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET.
Watanabe H; Inoue T; Shinozaki T; Yanagawa T; Ahmed AR; Tomiyoshi K; Oriuchi N; Tokunaga M; Aoki J; Endo K; Takagishi K
Eur J Nucl Med; 2000 Oct; 27(10):1509-17. PubMed ID: 11083540
[TBL] [Abstract][Full Text] [Related]
20. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer.
Adams S; Baum RP; Stuckensen T; Bitter K; Hör G
Eur J Nucl Med; 1998 Sep; 25(9):1255-60. PubMed ID: 9724374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
